Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055.

Marshall, Gayle; Howard, Zoe; Dry, Jonathan; Fenton, Sarah; Heathcote, Dan; Gray, Neil; Keen, Heather; Logie, Armelle; Holt, Sarah; Smith, Paul; Guichard, Sylvie M

Marshall, Gayle; Howard, Zoe; Dry, Jonathan; Fenton, Sarah; Heathcote, Dan; Gray, Neil; Keen, Heather; Logie, Armelle; Holt, Sarah; Smith, Paul; Guichard, Sylvie M.

Affiliation

Marshall G; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.

Biochem Soc Trans ; 39(2): 456-9, 2011 Apr.

Article in En | MEDLINE | ID: mdl-21428919

Subject(s)

Medical Oncology/methods; Morpholines/therapeutic use; Neoplasms/drug therapy; Protein Kinase Inhibitors/therapeutic use; TOR Serine-Threonine Kinases/antagonists & inhibitors; Animals; Antineoplastic Agents/therapeutic use; Drug Evaluation, Preclinical; Humans; Molecular Targeted Therapy/methods; Protein Kinase Inhibitors/pharmacology; Sirolimus/analogs & derivatives; Sirolimus/pharmacology; Sirolimus/therapeutic use

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Morpholines / Protein Kinase Inhibitors / TOR Serine-Threonine Kinases / Medical Oncology / Neoplasms Type of study: Evaluation_studies Limits: Animals / Humans Language: En Journal: Biochem Soc Trans Year: 2011 Document type: Article Affiliation country: United kingdom Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google